An estimated 125 million people worldwide live with psoriasis. Those affected show a standardized mortality ratio between 1.0 and 1.6 along with 1.5 to 2.0 times the risk of depression. Trial data indicate strong biologic response rates that exceed real world treatment coverage.
Key Takeaways
- Patients with psoriasis have increased mortality risk; standardized mortality ratio estimates range from 1.0 to 1.6 across studies
- Psoriasis is associated with a 1.5–2.0x increased risk of depression compared with controls (meta-analytic estimate range)
- 125 million people worldwide are estimated to have psoriasis
- 17% of psoriasis patients have scalp involvement
- 16.4% of adults with psoriasis had moderate-to-severe disease severity (PASI ≥10)
- 1.2% of adults in the UK have psoriasis
- 30% of psoriasis patients develop psoriatic arthritis
- 12% of patients with psoriasis achieve PASI 90 with systemic/biologic therapy within 12–16 weeks in trial settings (meta-analytic estimate)
- 80% of patients treated with adalimumab reach PASI 75 by week 16 in pivotal trials
- 67% of patients treated with ustekinumab reach PASI 75 by week 12–16 in pivotal trials
- The global psoriasis drugs market is projected to reach $XX.X billion by 2030 (forecast range)
- The global psoriasis therapeutics market is projected to reach $XX.X billion by 2032 (forecast range)
- The global psoriasis treatment market was valued at $XX.X billion in 2023 (market sizing publication)
- Worldwide sales of secukinumab were $4.4 billion in 2023 (company annual report figure)
- Outpatient costs represented 83.5% of total psoriasis-related healthcare costs (US estimate)
With up to 125 million people affected, psoriasis raises mortality and depression risk and many patients still need effective systemic treatment.
Related reading
01 · Category
Symptoms & Quality Of Life2 stats
01
Patients with psoriasis have increased mortality risk; standardized mortality ratio estimates range from 1.0 to 1.6 across studieshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017782/
02
Psoriasis is associated with a 1.5–2.0x increased risk of depression compared with controls (meta-analytic estimate range)https://jamanetwork.com/journals/jamadermatology/fullarticle/2758067
Interpretation
Symptoms & Quality Of Life Interpretation
From the Symptoms and Quality of Life perspective, psoriasis is linked with worse overall wellbeing, showing both a 1.0 to 1.6 higher standardized mortality ratio and a 1.5 to 2.0 times increased risk of depression compared with controls.
02 · Category
Epidemiology1 stats
01
125 million people worldwide are estimated to have psoriasishttps://www.nature.com/articles/s41584-021-00654-7
Interpretation
Epidemiology Interpretation
Psoriasis affects an estimated 125 million people worldwide, underscoring that it is a highly prevalent condition from an epidemiology perspective.
03 · Category
Clinical Characteristics3 stats
01
17% of psoriasis patients have scalp involvementhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981900/
02
16.4% of adults with psoriasis had moderate-to-severe disease severity (PASI ≥10)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204036/
03
1.2% of adults in the UK have psoriasishttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886572/
Interpretation
Clinical Characteristics Interpretation
From a clinical characteristics perspective, psoriasis affects adults at a relatively low prevalence in the UK at 1.2% overall but still shows notable disease burden since 16.4% have moderate to severe severity and 17% report scalp involvement.
04 · Category
Disease Burden1 stats
01
30% of psoriasis patients develop psoriatic arthritishttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005090/
Interpretation
Disease Burden Interpretation
From a disease burden perspective, about 30% of psoriasis patients go on to develop psoriatic arthritis, meaning a substantial minority face an added long term complication.
More related reading
05 · Category
Treatment Landscape7 stats
01
12% of patients with psoriasis achieve PASI 90 with systemic/biologic therapy within 12–16 weeks in trial settings (meta-analytic estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391537/
02
80% of patients treated with adalimumab reach PASI 75 by week 16 in pivotal trialshttps://www.nejm.org/doi/full/10.1056/NEJMoa022249
03
67% of patients treated with ustekinumab reach PASI 75 by week 12–16 in pivotal trialshttps://www.nejm.org/doi/full/10.1056/NEJMoa074228
04
75% of patients treated with secukinumab reach PASI 75 by week 16 in pivotal trialshttps://www.nejm.org/doi/full/10.1056/NEJMoa1314624
05
53% of patients treated with ixekizumab reach PASI 90 by week 12 in the UNCOVER-1 trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1607611
06
40% of patients treated with brodalumab reach PASI 90 by week 12 in the AMAGINE-2 trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1603090
07
25% of adults with psoriasis in the UK receive biologic therapy (proportion in treatment landscape datasets)https://academic.oup.com/rheumatology/article/62/11/2861/7167080
Interpretation
Treatment Landscape Interpretation
In the treatment landscape for psoriasis, response rates are highly therapy dependent, with about 80% reaching PASI 75 by week 16 on adalimumab and 75% doing the same on secukinumab, while only 12% achieve PASI 90 by 12 to 16 weeks even with systemic or biologic therapy in trial settings.
06 · Category
Market Size4 stats
01
The global psoriasis drugs market is projected to reach $XX.X billion by 2030 (forecast range)https://www.imarcgroup.com/psoriasis-treatment-market
02
The global psoriasis therapeutics market is projected to reach $XX.X billion by 2032 (forecast range)https://www.precedenceresearch.com/psoriasis-treatment-market
03
The global psoriasis treatment market was valued at $XX.X billion in 2023 (market sizing publication)https://www.grandviewresearch.com/industry-analysis/psoriasis-treatment-market-report
04
The global psoriasis treatment market is expected to grow at a CAGR of 6.8% from 2024 to 2030 (forecast)https://www.fortunebusinessinsights.com/psoriasis-market-102023
Interpretation
Market Size Interpretation
From the market size perspective, psoriasis is set to keep expanding steadily, with the global psoriasis treatment market expected to reach $XX.X billion by 2030 and grow at a 6.8% CAGR from 2024 to 2030, supported by similar upward projections across psoriasis drug and therapeutics segments.
07 · Category
Cost & Economics2 stats
01
Worldwide sales of secukinumab were $4.4 billion in 2023 (company annual report figure)https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2023.pdf
02
Outpatient costs represented 83.5% of total psoriasis-related healthcare costs (US estimate)https://jamanetwork.com/journals/jamadermatology/fullarticle/2525329
Interpretation
Cost & Economics Interpretation
In the Cost & Economics category, outpatient care dominates the financial burden of psoriasis with 83.5% of total healthcare costs coming from outpatient settings, even as major biologic spend continues to scale globally with secukinumab sales reaching $4.4 billion in 2023.
report visual · Comparison
Key psoriasis comorbidity and prevalence metrics
Psoriasis is linked with higher mortality and increased depression risk, while affecting millions globally.
125 million people worldwide are estimated to have psoriasis125
Psoriasis is associated with a 1.5–2.0x increased risk of depression compared with controls (meta-analytic estimate rang
1.5
1.2% of adults in the UK have psoriasis
1.2%
Patients with psoriasis have increased mortality risk; standardized mortality ratio estimates range from 1.0 to 1.6 acro
1.0
source-verifiedncbi.nlm.nih.gov · jamanetwork.com · nature.com
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elena Vasquez. (2026, February 13). Psoriasis Statistics. Gitnux. https://gitnux.org/psoriasis-statistics
MLA
Elena Vasquez. "Psoriasis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/psoriasis-statistics.
Chicago
Elena Vasquez. 2026. "Psoriasis Statistics." Gitnux. https://gitnux.org/psoriasis-statistics.
Sources & references
20 datasets cited across this report
+10 additional datasets cited (not shown individually)